Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jun 25;321(24):2414-2427.
doi: 10.1001/jama.2019.8145.

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial

Hirotoshi Watanabe  1 , Takenori Domei  2 , Takeshi Morimoto  3 , Masahiro Natsuaki  4 , Hiroki Shiomi  1 , Toshiaki Toyota  5 , Masanobu Ohya  6 , Satoru Suwa  7 , Kensuke Takagi  8 , Mamoru Nanasato  9 , Yoshiki Hata  10 , Masahiro Yagi  11 , Nobuhiro Suematsu  12 , Takafumi Yokomatsu  13 , Itaru Takamisawa  14 , Masayuki Doi  15 , Toshiyuki Noda  16 , Hideki Okayama  17 , Yoshitane Seino  18 , Tomohisa Tada  19 , Hiroki Sakamoto  19 , Kiyoshi Hibi  20 , Mitsuru Abe  21 , Kazuya Kawai  22 , Koichi Nakao  23 , Kenji Ando  2 , Kengo Tanabe  24 , Yuji Ikari  25 , Keiichi Igarashi Hanaoka  26 , Yoshihiro Morino  27 , Ken Kozuma  28 , Kazushige Kadota  6 , Yutaka Furukawa  5 , Yoshihisa Nakagawa  29 , Takeshi Kimura  1 ; STOPDAPT-2 Investigators
Affiliations
Randomized Controlled Trial

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial

Hirotoshi Watanabe et al. JAMA. .

Abstract

Importance: Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option.

Objective: To test the hypothesis of noninferiority of 1 month of DAPT compared with standard 12 months of DAPT for a composite end point of cardiovascular and bleeding events.

Design, setting, and participants: Multicenter, open-label, randomized clinical trial enrolling 3045 patients who underwent PCI at 90 hospitals in Japan from December 2015 through December 2017. Final 1-year clinical follow-up was completed in January 2019.

Interventions: Patients were randomized either to 1 month of DAPT followed by clopidogrel monotherapy (n=1523) or to 12 months of DAPT with aspirin and clopidogrel (n=1522).

Main outcomes and measures: The primary end point was a composite of cardiovascular death, myocardial infarction (MI), ischemic or hemorrhagic stroke, definite stent thrombosis, or major or minor bleeding at 12 months, with a relative noninferiority margin of 50%. The major secondary cardiovascular end point was a composite of cardiovascular death, MI, ischemic or hemorrhagic stroke, or definite stent thrombosis and the major secondary bleeding end point was major or minor bleeding.

Results: Among 3045 patients randomized, 36 withdrew consent; of 3009 remaining, 2974 (99%) completed the trial. One-month DAPT was both noninferior and superior to 12-month DAPT for the primary end point, occurring in 2.36% with 1-month DAPT and 3.70% with 12-month DAPT (absolute difference, -1.34% [95% CI, -2.57% to -0.11%]; hazard ratio [HR], 0.64 [95% CI, 0.42-0.98]), meeting criteria for noninferiority (P < .001) and for superiority (P = .04). The major secondary cardiovascular end point occurred in 1.96% with 1-month DAPT and 2.51% with 12-month DAPT (absolute difference, -0.55% [95% CI, -1.62% to 0.52%]; HR, 0.79 [95% CI, 0.49-1.29]), meeting criteria for noninferiority (P = .005) but not for superiority (P = .34). The major secondary bleeding end point occurred in 0.41% with 1-month DAPT and 1.54% with 12-month DAPT (absolute difference, -1.13% [95% CI, -1.84% to -0.42%]; HR, 0.26 [95% CI, 0.11-0.64]; P = .004 for superiority).

Conclusions and relevance: Among patients undergoing PCI, 1 month of DAPT followed by clopidogrel monotherapy, compared with 12 months of DAPT with aspirin and clopidogrel, resulted in a significantly lower rate of a composite of cardiovascular and bleeding events, meeting criteria for both noninferiority and superiority. These findings suggest that a shorter duration of DAPT may provide benefit, although given study limitations, additional research is needed in other populations.

Trial registration: ClinicalTrials.gov Identifier: NCT02619760.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Watanabe reported receipt of personal fees from Abbott Vascular Japan and Daiichi Sankyo. Dr Yagi reported receipt of personal fees from Otsuka Pharmaceutical, Daiichi Sankyo, and Kowa Pharmaceuticals. Dr Hibi reported receipt of personal fees from Abbott Vascular. Dr Nakao reported receipt of personal fees from Sanofi, Bayer, Daiichi-Sankyo, and Boehringer Ingelheim. Dr Tanabe reported receipt of personal fees from Abbott Vascular, AstraZeneca, Sanofi, Daiichi Sankyo, Terumo, Boston Scientific, Japan Lifeline, Bayer, and Medtronic and advisory board membership for Abbott Vascular and Terumo Japan. Dr Morino reported receipt of personal fees from Abbott Vascular and advisory board membership for Abbott Vascular and Terumo Japan. Dr Kozuma reported receipt of grants and personal fees from Abbott Vascular and advisory board membership for Abbott Vascular and Terumo Japan. Dr Furukawa reported receipt of personal fees from Daiichi Sankyo, Bayer, and Sanofi. Dr Nakagawa reported advisory board membership for Abbott Vascular. Dr Kimura reported receipt of personal fees from Abbott Vascular and grants from Abbott Vascular and Boston Scientific and advisory board membership for Abbott Vascular and Terumo Japan. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Participant Flow in the STOPDAPT-2 Randomized Clinical Trial
CoCr-EES indicates cobalt-chromium everolimus-eluting stent. aA total of 183 patients had planned staged procedure and received other drug-eluting stents, so numbers are not mutually exclusive.
Figure 2.
Figure 2.. One-Year Time to Events for the Primary and Major Secondary End Points
HR indicates hazard ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction. The median observation periods in the last data set were 400 (interquartile range, 368-732) days in the 1-month dual antiplatelet therapy (DAPT) group and 414 (interquartile range, 369-733) days in the 12-month DAPT group. The last day of data collection was day 365; patients with follow-up beyond 1 year were censored on day 366.
Figure 3.
Figure 3.. Subgroup Analyses for the Effect of 1-Month DAPT on the Primary End Point
CREDO-Kyoto indicates Coronary Revascularization Demonstrating Outcome Study in Kyoto; HR, hazard ratio; PARIS, Patterns of Non-Adherence to Anti-Platelet Regimen in Stented Patients; STEMI, ST-segment elevation myocardial infarction. The vertical dashed line indicates the prespecified relative 50% noninferiority margin. Numbers and percentages shown are number of patients with event/number of patients at risk and incidences at 1 year. Acute coronary syndrome was the clinical presentation for the index percutaneous coronary intervention. Severe chronic kidney disease is defined as preprocedural estimated glomerular filtration rate less than 30 mL/min/1.73 m2 or undergoing maintenance dialysis. See Table 1 for definitions of PARIS and CREDO-Kyoto risk scores.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Levine GN, Bates ER, Bittl JA, et al. . 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123-e155. - PubMed
    1. Valgimigli M, Bueno H, Byrne RA, et al. ; ESC Scientific Document Group; ESC Committee for Practice Guidelines; ESC National Cardiac Societies . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260. doi:10.1093/eurheartj/ehx419 - DOI - PubMed
    1. Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. . Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385(9985):2371-2382. doi:10.1016/S0140-6736(15)60263-X - DOI - PubMed
    1. Toyota T, Shiomi H, Morimoto T, Natsuaki M, Kimura T. Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: a comparison between the DAPT study and 9 other trials evaluating DAPT duration. PLoS One. 2017;12(9):e0174502. doi:10.1371/journal.pone.0174502 - DOI - PMC - PubMed
    1. Mauri L, Kereiakes DJ, Yeh RW, et al. ; DAPT Study Investigators . Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-2166. doi:10.1056/NEJMoa1409312 - DOI - PMC - PubMed

MeSH terms

Associated data